A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Trastuzumab is a standard treatment for HER2-positive (HER2(+)) breast cancer, but some patients are refractory to the therapy. MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2(+) metastatic breast cancer (MBC)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Li, Huiping, Liu, Jiang, Chen, Jianing, Wang, Huiyun, Yang, Linbin, Chen, Fei, Fan, Siting, Wang, Jing, Shao, Bin, Yin, Dong, Zeng, Musheng, Li, Mengfeng, Li, Jun, Su, Fengxi, Liu, Qiang, Yao, Herui, Su, Shicheng, Song, Erwei
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915573/
https://ncbi.nlm.nih.gov/pubmed/29691399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-03537-w
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars